ACE Inhibitors and Persistent Left Ventricular Hypertrophy After Renal Transplantation: A Randomized Clinical Trial

American Journal of Kidney Diseases

Volumn 50, Issue 1, 2007, Pages 133-142

  Paoletti, Ernesto ^a   Cassottana, Paolo ^a   Amidone, Marco ^a   Gherzi, Maurizio ^a   Rolla, Davide ^a   Cannella, Giuseppe ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

angiotensin converting enzyme (ACE) inhibitors; cyclosporine; Left ventricular hypertrophy; renal transplant recipients; tacrolimus

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LISINOPRIL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID; TACROLIMUS;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; ECHOCARDIOGRAPHY; FEMALE; GRAFT REJECTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY TRANSPLANTATION; MALE; MULTIPLE REGRESSION; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LINEAR MODELS; LISINOPRIL; MALE; MIDDLE AGED; TACROLIMUS;

EID: 34250732723     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2007.04.013     Document Type: Article

References (27)

1. Rigatto C., and Parfrey P. Therapy insights: Management of cardiovascular disease in the renal transplant recipient. Nat Clin Pract Nephrol 2 (2006) 514-526
2. Rigatto C., Foley R.N., Jeffery J., et al. Electrocardiographic left ventricular hypertrophy in renal transplant recipients: Prognostic value and impact of blood pressure and anemia. J Am Soc Nephrol 14 (2003) 462-468
3. Foley R.N., Parfrey P.S., and Sarnak M.J. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 32 suppl 3 (1998) S112-S119
4. Parfrey P.S., Harnett J.D., Foley R.N., et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation 60 (1995) 908-914
5. Hernandez D., Lacalzada J., Salido E., et al. Regression of left ventricular hypertrophy by lisinopril after renal transplantation: Role of ACE gene polymorphism. Kidney Int 58 (2000) 889-897
6. Midtvedt K., Ihlen H., Hartmann A., et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: A prospective randomized double-blind study. Transplantation 72 (2001) 107-111
7. London G.M., Pannier B., Guerin A.P., et al. Cardiac hypertrophy, aortic compliance, peripheral resistance and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation 90 (1994) 2786-2796
8. Cannella G., Paoletti E., Delfino R., et al. Prolonged therapy with ACE inhibitors induces a regression of left ventricular hypertrophy of dialyzed uremic patients independently from hypotensive effects. Am J Kidney Dis 30 (1997) 659-664
9. Ferrara L.A., Vaccaro O., Cardoni O., et al. Indexation criteria of left ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens 18 (2005) 1263-1265
10. National Kidney Foundation. K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease. Am J Kidney Dis 43 suppl 1 (2004) S1-S290
11. Sahn D.J., De Maria A., Kisslo J., et al. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation 58 (1978) 1072-1083
12. Devereux R.B., Alonso D.R., Lutas E.M., et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necroscopy findings. Am J Cardiol 57 (1986) 450-458
13. Zoccali C., Benedetto F.A., Mallamaci F., et al. Prognostic impact of the indexation of left ventricular mass in patients undergoing dialysis. J Am Soc Nephrol 12 (2001) 2768-2774
14. Ganau A., Devereux R.B., Roman M.J., et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 19 (1992) 1550-1558
15. Heinze G., Mitterbauer C., Regele H., et al. Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 17 (2006) 889-899
16. Molkentin J.D., Lu J.R., Antos C.R., et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 (1998) 215-228
17. Zhang W., Kowal R.C., Rusnak F., et al. Failure of calcineurin inhibitors to prevent pressure-overload left ventricular hypertrophy in rats. Circ Res 84 (1999) 722-728
18. Sakata Y., Masuyama T., Yamamoto K., et al. Calcineurin inhibitor attenuates left ventricular hypertrophy, leading to prevention of heart failure in hypertensive rats. Circulation 102 (2000) 2269-2275
19. Chang R.K., Alzona M., Alejos J., et al. Marked left ventricular hypertrophy in children on tacrolimus (FK506) after orthotopic liver transplantation. Am J Cardiol 81 (1998) 1277-1280
20. Coley K.C., Verrico M.M., McNamara D.M., et al. Lack of tacrolimus-induced cardiomyopathy. Ann Pharmacother 35 (2001) 985-989
21. Lee D.B.N. Cyclosporine and the renin-angiotensin axis. Kidney Int 52 (1997) 248-260
22. Schmieder R.E., Lagenfeld M.R.W., Friedrich A., et al. Angiotensin II related to sodium excretion modulates left ventricular structure in human essential hypertension. Circulation 94 (1996) 1304-1309
23. Schmieder R.E., Schlaich M.P., Klingbeil A.U., et al. Update on reversal of left ventricular hypertrophy in essential hypertension (a meta-analysis of all randomized double-blind studies until December 1996). Nephrol Dial Transplant 13 (1998) 564-569
24. Covic A., Mardare N., Gusbeth-Tatomir P., et al. Acute effect of CyA A (Neoral) on large artery hemodynamics in renal transplant patients. Kidney Int 67 (2005) 732-737
25. London G.M., Pannier B., Vicaut E., et al. Antihypertensive effects and arterial hemodynamic alterations during angiotensin converting enzyme inhibition. J Hypertens 14 (1996) 1139-1146
26. Paoletti E., Cassottana P., Bellino D., et al. Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors. Am J Kidney Dis 40 (2002) 728-736
27. Shimamoto H., and Shimamoto Y. Lisinopril reverses left ventricular hypertrophy through improved aortic compliance. Hypertension 28 (1996) 457-463